August 2012
-
Adamis Pharmaceuticals has announced that a clinical study comparing its APC-2000 albuterol MDI with GSK’s Ventolin Evohaler MDI met its primary endpoint, showing equivalence in change from baseline of FEV1 for both doses tested (100… Read more . . .
-
AstraZeneca announced that it has entered into a five-year partnership agreement with patient network PatientsLikeMe for access to patient-reported data in several treatment areas, including respiratory. PatientsLikeMe offers a program called “data for good,” whose… Read more . . .
-
CDMO Molecular Profiles has announced that the company has a new name: Juniper Pharma Services. The company, whose services include formulation development and clinical trial manufacturing of dry powder inhalers, was acquired in 2013 by… Read more . . .
-
Vectura has announced that it will close the former Activaero nebulizer manufacturing site in Gemünden, Germany by March 2016, transfering many of the site’s operations to other Vectura facilities in Germany and the UK. Commercial… Read more . . .
-
The European Patent Office has granted Evoke Pharma patent no. 2376075 for its EVK-001 intranasal metoclopramide for the treatment of diabetic gastroparesis symptoms in women, the company said. Earlier this year, Evoke announced that Phase… Read more . . .
-
Aptar Pharma has announced that the Chinese State Food and Drug Administration (SFDA) has issued the company an import license for its preservative-free multi-dose opthalmic and nasal devices in accordance with regulations that require “Examination… Read more . . .
-
PARI Pharma has received European marketing authorization for its Vantobra 170 mg tobramycin/1.7 ml inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients aged 6 and older, the company said. Vantobra… Read more . . .
-
Optimizing a dry powder inhaler (DPI) to achieve the desired emitted dose and aerodynamic particle size distribution (APSD) can be made significantly faster and easier by using data acquired by laser diffraction and morphologically directed… Read more . . .
-
Respiratory drug developer Vectura has announced the appointment of former Almirall Executive Director of R&D Per-Olof Andersson as a Non-Executive Director of the Board. Before Almirall, he worked for almost two decades for Pharmacia and… Read more . . .
-
Aptar Pharma has announced that a new budesonide DPI launched in China by Shanghai Sine Promod Pharmaceutical is the first marketed product to incorporate Aptar’s new Twister device. The new 200µg dose budesonide inhaler is… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.